TrialJournal of neurology2015

An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.

Eppie M Yiu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.